{{Short description|Peptide drug}} {{Use dmy dates|date=September 2025}} {{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = | ATCvet = | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = <!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US_comment = | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = <!-- For countries not listed above --> <!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = <!-- Identifiers --> | synonyms = BI 456906; EX-A7878 | CAS_number = 2805997-46-8 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2ALA66NS64 | PubChem = 168429725 | DrugBank = | KEGG = D12898 <!-- Chemical and physical data --> | IUPAC_name = | StdInChI=1S/C192H289N47O61/c1-12-103(6)157(186(295)221-122(170(279)227-134(83-113-88-203-119-48-34-33-47-117(113)119)177(286)223-128(77-101(2)3)173(282)219-126(66-70-153(261)262)172(281)232-140(97-242)183(292)210-104(7)160(197)269)51-37-40-75-201-146(252)90-205-147(253)91-206-165(274)138(95-240)215-149(255)93-208-166(275)139(96-241)214-148(254)92-204-144(250)68-64-127(189(298)299)213-145(251)53-31-23-21-19-17-15-13-14-16-18-20-22-24-32-54-151(257)258)237-181(290)132(79-109-43-27-25-28-44-109)226-179(288)136(86-155(265)266)228-168(277)120(49-35-38-73-193)216-162(271)106(9)211-161(270)105(8)212-167(276)123(52-41-76-202-191(198)199)217-171(280)125(65-69-152(259)260)220-178(287)135(85-154(263)264)229-174(283)129(78-102(4)5)222-175(284)130(81-111-55-59-115(247)60-56-111)224-169(278)121(50-36-39-74-194)218-184(293)141(98-243)233-176(285)131(82-112-57-61-116(248)62-58-112)225-180(289)137(87-156(267)268)230-185(294)142(99-244)234-188(297)159(108(11)246)238-182(291)133(80-110-45-29-26-30-46-110)231-187(296)158(107(10)245)236-150(256)94-207-164(273)124(63-67-143(196)249)235-190(300)192(71-42-72-192)239-163(272)118(195)84-114-89-200-100-209-114/h25-30,33-34,43-48,55-62,88-89,100-108,118,120-142,157-159,203,240-248H,12-24,31-32,35-42,49-54,63-87,90-99,193-195H2,1-11H3,(H2,196,249)(H2,197,269)(H,200,209)(H,201,252)(H,204,250)(H,205,253)(H,206,274)(H,207,273)(H,208,275)(H,210,292)(H,211,270)(H,212,276)(H,213,251)(H,214,254)(H,215,255)(H,216,271)(H,217,280)(H,218,293)(H,219,282)(H,220,287)(H,221,295)(H,222,284)(H,223,286)(H,224,278)(H,225,289)(H,226,288)(H,227,279)(H,228,277)(H,229,283)(H,230,294)(H,231,296)(H,232,281)(H,233,285)(H,234,297)(H,235,300)(H,236,256)(H,237,290)(H,238,291)(H,239,272)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,298,299)(H4,198,199,202)/t103-,104+,105-,106-,107+,108+,118-,120-,121-,122+,123-,124-,125-,126+,127?,128+,129-,130+,131-,132-,133-,134+,135-,136-,137-,138+,139+,140+,141-,142-,157-,158-,159-/m0/s1 | StdInChIKey = MEDXQFAHWBMVIM-YIUAJOCSSA-N | SMILES = CC[C@H](C)[C@@H](C(=O)N[C@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N | Jmol = none | C = 192 | H = 289 | N = 47 | O = 61 }}
'''Survodutide''' ('''BI 456906''') is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin. It is developed by Boehringer Ingelheim as a weight loss drug.<ref>{{cite journal |last1=Klein |first1=Thomas |last2=Augustin |first2=Robert |last3=Hennige |first3=Anita M. |title=Perspectives in weight control in diabetes – BI 456906 |journal=Diabetes Research and Clinical Practice |date=June 2023 |volume=207 |article-number=110779 |doi=10.1016/j.diabres.2023.110779|pmid=37330144 |s2cid=259188902 |doi-access=free }}</ref><ref>{{cite journal |last1=Zimmermann |first1=Tina |last2=Thomas |first2=Leo |last3=Baader-Pagler |first3=Tamara |last4=Haebel |first4=Peter |last5=Simon |first5=Eric |last6=Reindl |first6=Wolfgang |last7=Bajrami |first7=Besnik |last8=Rist |first8=Wolfgang |last9=Uphues |first9=Ingo |last10=Drucker |first10=Daniel J. |last11=Klein |first11=Holger |last12=Santhanam |first12=Rakesh |last13=Hamprecht |first13=Dieter |last14=Neubauer |first14=Heike |last15=Augustin |first15=Robert |title=BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy |journal=Molecular Metabolism |date=December 2022 |volume=66 |article-number=101633 |doi=10.1016/j.molmet.2022.101633|doi-access=free |pmid=36356832 |pmc=9679702 }}</ref><ref>{{cite journal |last1=Augustin |first1=Robert |last2=Thomas |first2=Leo |last3=Zimmermann |first3=Tina |last4=Simon |first4=Eric |last5=Rist |first5=Wolfgang |last6=Uphues |first6=Ingo |last7=Reindl |first7=Wolfgang |last8=Klein |first8=Thomas |last9=Neubauer |first9=Heike |title=749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers |journal=Diabetes |date=20 June 2023 |volume=72 |issue=Supplement_1 |article-number=749-P |doi=10.2337/db23-749-P|s2cid=259442329 }}</ref>
Survodutide is a twincretin having dual glucagon-like peptide-1 and glucagon receptor agonist activity, conceptually based on endogenous peptide oxyntomodulin. In a meta-analysis involving data from 3 randomized controlled trials having 1088 patients, 4- 11 months use of survodutide at doses 2.4-4.8 mg / week was associated with on an average 7-9% reduction in body weight from baseline. This translates to around 9-15kg of body weight reduction from baseline. Gastrointestinal side effects were the predominant side effects, were mild and dose dependent, as has been noted with other incretin based therapies.<ref>{{cite journal | vauthors = Dutta D, Kamrul-Hasan AB, Joshi A, Dhall A, Nagendra L, Sharma M | title = Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis. | journal = Indian J Endocrinol Metab | volume = 29 | issue = 3 | date = May–Jun 2025 | pages = 253–259 | pmid = 40688625 | doi = 10.4103/ijem.ijem_366_24 | pmc = 12274044 | doi-access = free }}</ref>
==References== {{reflist}}
Category:Peptide therapeutics Category:Glucagon receptor agonists Category:GLP-1 receptor agonists Category:Drugs developed by Boehringer Ingelheim Category:Experimental anti-obesity drugs